Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Michele Fox to Multiple Myeloma

This is a "connection" page, showing publications Michele Fox has written about Multiple Myeloma.

 
Connection Strength
  
 
 
1.947
  
  1. Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707.
    View in: PubMed
    Score: 0.169
  2. Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res. 2017 Jun 01; 23(11):2665-2672.
    View in: PubMed
    Score: 0.102
  3. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36.
    View in: PubMed
    Score: 0.090
  4. Abuabdou A, Rosenbaum ER, Usmani SZ, Barlogie B, Cottler-Fox M. Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables. J Clin Apher. 2014 Oct; 29(5):251-5.
    View in: PubMed
    Score: 0.083
  5. Papanikolaou X, Rosenbaum ER, Tyler LN, Sawyer J, Heuck CJ, Barlogie B, Cottler-Fox M. Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia. Leukemia. 2014 Apr; 28(4):888-93.
    View in: PubMed
    Score: 0.081
  6. Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun 06; 121(23):4753-7.
    View in: PubMed
    Score: 0.080
  7. Muzaffar J, Usmani S, Abdallah AO, Anaissie E, Cottler-Fox M, Restrepo A. High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):171-4.
    View in: PubMed
    Score: 0.078
  8. Post GR, James L, Alapat D, Guillory V, Cottler-Fox M, Nakagawa M. A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange. Transfus Apher Sci. 2013 Feb; 48(1):35-8.
    View in: PubMed
    Score: 0.076
  9. Fassas AB, Rapoport AP, Bola?os-Meade J, Shanholtz C, Cottler-Fox M, Tricot G. Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1323-8.
    View in: PubMed
    Score: 0.072
  10. Fassas AB, Bola?os-Meade J, Buddharaju LN, Rapoport A, Cottler-Fox M, Chen T, Lovchik JC, Cross A, Tricot G. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol. 2001 Jan; 112(1):237-41.
    View in: PubMed
    Score: 0.068
  11. Veeraputhiran M, Theus JW, Pesek G, Barlogie B, Cottler-Fox M. Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage dimethyl sulfoxide concentration. Cytotherapy. 2010 Oct; 12(6):764-6.
    View in: PubMed
    Score: 0.067
  12. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008 Dec; 143(5):641-53.
    View in: PubMed
    Score: 0.058
  13. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica. 2008 Nov; 93(11):1739-42.
    View in: PubMed
    Score: 0.058
  14. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008 Jan 01; 111(1):94-100.
    View in: PubMed
    Score: 0.054
  15. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007 Jul; 138(2):176-85.
    View in: PubMed
    Score: 0.053
  16. Shaughnessy JD, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007 Jun; 137(6):530-6.
    View in: PubMed
    Score: 0.053
  17. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84.
    View in: PubMed
    Score: 0.051
  18. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006 Feb; 91(2):192-9.
    View in: PubMed
    Score: 0.048
  19. Cottler-Fox M, Lapidot T. Mobilizing the older patient with myeloma. Blood Rev. 2006 Jan; 20(1):43-50.
    View in: PubMed
    Score: 0.047
  20. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004 Mar 15; 64(6):2016-23.
    View in: PubMed
    Score: 0.042
  21. Bayer-Garner IB, Cottler-Fox M, Smoller BR. Sweet syndrome in multiple myeloma: a series of six cases. J Cutan Pathol. 2003 Apr; 30(4):261-4.
    View in: PubMed
    Score: 0.040
  22. Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, Barlogie B, Cottler-Fox M. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002 Feb; 42(2):205-9.
    View in: PubMed
    Score: 0.037
  23. Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010 Sep; 150(5):554-64.
    View in: PubMed
    Score: 0.033
  24. Pandey S, Cottler-Fox M. Optia? continuous mononuclear collection (CMNC) system is a safe and efficient system for hematopoietic progenitor cells-apheresis (HPC-a) collection and yields a lower product hematocrit (HCT%) than the COBE? spectra system: A retrospective study. J Clin Apher. 2018 Aug; 33(4):505-513.
    View in: PubMed
    Score: 0.028
  25. Pandey S, Rosenbaum E, Cottler-Fox M, Harville TO. Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches. Ann Clin Lab Sci. 2017 May; 47(3):315-318.
    View in: PubMed
    Score: 0.026
  26. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 09; 354(10):1021-30.
    View in: PubMed
    Score: 0.024
  27. Lee CK, Zangari M, Fassas A, Thertulien R, Talamo G, Badros A, Cottler-Fox M, van Rhee F, Barlogie B, Tricot G. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant. 2006 Mar; 37(5):511-5.
    View in: PubMed
    Score: 0.024
  28. Grazziutti ML, Dong L, Miceli MH, Cottler-Fox M, Krishna SG, Fassas A, van Rhee F, Barlogie BM, Anaissie EJ. Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients. Bone Marrow Transplant. 2006 Feb; 37(4):403-9.
    View in: PubMed
    Score: 0.024
  29. Gojo I, Meisenberg B, Guo C, Fassas A, Murthy A, Fenton R, Takebe N, Heyman M, Philips GL, Cottler-Fox M, Sarkodee-Adoo C, Ruehle K, French T, Tan M, Tricot G, Rapoport AP. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant. 2006 Jan; 37(1):65-72.
    View in: PubMed
    Score: 0.024
  30. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 1995 Jun 01; 85(11):3048-57.
    View in: PubMed
    Score: 0.023
  31. Cottler-Fox M, Cipolone K, Yu M, Berenson R, O'Shaughnessy J, Dunbar C. Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation. Exp Hematol. 1995 Apr; 23(4):320-2.
    View in: PubMed
    Score: 0.023
  32. Szmania S, Yi Q, Cottler-Fox M, Rosen NA, Freeman J, Kordsmeier BJ, Moreno A, Shi J, Barlogie B, Tricot G, van Rhee F. Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation. Cytotherapy. 2005; 7(4):374-84.
    View in: PubMed
    Score: 0.022
  33. Gojo I, Guo C, Sarkodee-Adoo C, Meisenberg B, Fassas A, Rapoport AP, Cottler-Fox M, Heyman M, Takebe N, Tricot G. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant. 2004 Jul; 34(1):69-76.
    View in: PubMed
    Score: 0.022
  34. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9.
    View in: PubMed
    Score: 0.020
  35. Dunbar CE, Nienhuis AW, Stewart FM, Quesenberry P, O'Shaughnessy J, Cowan K, Cottler-Fox M, Leitman S, Goodman S, Sorrentino BP, et al. Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer. Hum Gene Ther. 1993 Apr; 4(2):205-22.
    View in: PubMed
    Score: 0.020
  36. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003 Feb; 120(3):413-23.
    View in: PubMed
    Score: 0.020
  37. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80.
    View in: PubMed
    Score: 0.020
  38. Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant. 2002 Dec; 30(12):873-8.
    View in: PubMed
    Score: 0.019
  39. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002 Mar 01; 20(5):1295-303.
    View in: PubMed
    Score: 0.018
  40. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G, Aniassie E. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001 May 01; 97(9):2574-9.
    View in: PubMed
    Score: 0.017
  41. Fassas AB, Rapoport AP, Cottler-Fox M, Chen T, Tricot G. Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation. Br J Haematol. 2000 Nov; 111(2):662-7.
    View in: PubMed
    Score: 0.017
  42. Dunbar CE, Bodine DM, Sorrentino B, Donahue R, McDonagh K, Cottler-Fox M, O'Shaughnessy J, Cowan K, Carter C, Doren S, et al. Gene transfer into hematopoietic cells. Implications for cancer therapy. Ann N Y Acad Sci. 1994 May 31; 716:216-24; discussion 224-7.
    View in: PubMed
    Score: 0.005
  43. Cipolone KM, Carter CS, Yu M, Cottler-Fox M. A semi-automated process for antibody sensitization and washing of mononuclear cells prior to CD34+ cell selection. Prog Clin Biol Res. 1994; 389:667-73.
    View in: PubMed
    Score: 0.005
  44. Cassel A, Cottler-Fox M, Doren S, Dunbar CE. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol. 1993 Apr; 21(4):585-91.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.